Close
  Indian J Med Microbiol
 

Figure 3: CHRM1 activation promotes prostate cancer cell migration and invasion. (a) Representative images of the membrane infiltration of three cancer cell lines (PC-3, LNCaP, and A549 cells) after carbachol (a muscarinic receptor agonist) or pirenzepine (a CHRM1-specific antagonist) administration. Scale bars = 200 μm. (b) Quantification of infiltrated cells in the cell invasion assays. (c) Images of migration of the three tumor cell lines through the Matrigel-coated filter upon carbachol or pirenzepine administration. (d) Quantification of migrated cell numbers in the cell migration assays. Note that activation of CHRM1 significantly promoted the migration and invasion of the three cell lines. Cells were counted in five random fields per section. Error bars indicate standard error. *P < 0.05; **P < 0.01; ***P < 0.001. CHRM1: muscarinic acetylcholine receptor M1.

Figure 3: CHRM1 activation promotes prostate cancer cell migration and invasion. (<b>a</b>) Representative images of the membrane infiltration of three cancer cell lines (PC-3, LNCaP, and A549 cells) after carbachol (a muscarinic receptor agonist) or pirenzepine (a CHRM1-specific antagonist) administration. Scale bars = 200 μm. (<b>b</b>) Quantification of infiltrated cells in the cell invasion assays. (<b>c</b>) Images of migration of the three tumor cell lines through the Matrigel-coated filter upon carbachol or pirenzepine administration. (<b>d</b>) Quantification of migrated cell numbers in the cell migration assays. Note that activation of CHRM1 significantly promoted the migration and invasion of the three cell lines. Cells were counted in five random fields per section. Error bars indicate standard error. *<i>P</i> < 0.05; **<i>P</i> < 0.01; ***<i>P</i> < 0.001. CHRM1: muscarinic acetylcholine receptor M1.